30Jan

OGT unveils reliable somatic CNV detection for CLL with new NGS panel

Oxford, UK – 14 January 2020. Oxford Gene Technology (OGT), A Sysmex Group Company, is excited to announce the launch of its SureSeq CLL + CNV Panel — the company’s latest high-quality, next-generation sequencing (NGS) offering for research into Chronic Lymphocytic Leukaemia (CLL). The SureSeq CLL + CNV Panel fulfils the desire for reliable copy number variation (CNV) detection by NGS, including trisomy 12 and loss of heterozygosity (LOH), as well as somatic variants, even at low allele frequency. The panel, which has been tested to show excellent concordance with array data, can detect both small and large CNVs at 10% minor allele frequency (MAF), SNVs and indels down to 1% MAF and LOH at 5-10Mb.

 

The comprehensive panel covers all the most up-to-date, evidence-based genes and genomic aberrations for CLL and will enable laboratories to simplify their laboratory workflow by replacing multiple assays with a single one.

 

CLL is the most common type of leukaemia in adults and is associated with chromosomal aberrations ranging from somatic variants, to small and large CNVs, including trisomies. This complex genetic heterogeneity combined with a lack of sensitive and reliable NGS solutions has meant that currently scientists need to employ multiple methods to build a genomic profile of CLL samples.

 

One area in particular where NGS has traditionally struggled, is in the detection of CNVs, which can occur in important tumour suppressor genes, such as TP53. Additional techniques such as microarray, karyotyping or fluorescence in situ hybridisation (FISH) are often required to detect these CNVs and structural abnormalities, such as loss of heterozygosity (LOH) and trisomy 12.

 

The SureSeq CLL + CNV Panel was designed in collaboration with recognised cancer experts, as Emma Shipstone, Executive VP Marketing at OGT, highlights: “Having input from experienced cancer labs was instrumental in getting the design of the SureSeq CLL + CNV Panel spot on. This is CNV detection done well, yielding excellent data quality. This one assay can now replace the multiple assays historically necessary for the genomic profiling of CLL samples.”

 

For researchers, the single NGS panel simplifies the workflow and consolidates the profiling of the wide variety of genomic changes into a single analysis. Reliable data analyses can be carried out with OGT’s popular and easy-to-use Interpret software, a complementary and powerful software solution for accurate identification and visualisation of all variants including CNVs.

 

For more information please visit https://www.ogt.com/CLL.

 

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.

T: +44 (0) 1865 856800 ; F: +44 (0) 1865 848684

E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech

Related

MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated I...

Read More >

EKF Diagnostics supporting reduction of anemia in developing regions in South America

Symposium highlights successful use of EKF’s Hemo Control hemoglobin analyzer in extreme environmen...

Read More >

BBI Solutions & Dr C. Sturgeon consider International Standards for Cancer Biomarkers

Dr Catharine Sturgeon will be presenting her case for an international effort to align manufacturer’...

Read More >

A recent review by MIP Diagnostics Founder Sergey A. Piletsky from the University of Leicester and colleagues from Animal Health Research Institute

A recent review by MIP Diagnostics Founder Sergey A. Piletsky from the University of Leicester and c...

Read More >

First multi-site installation of HORIBA Medical’s new HELO modular automated haematology platform

Northampton, UK – 28th May 2019 – HORIBA UK Ltd, Medical announces the go live of the first multi-...

Read More >

SpeeDx Receives CE-IVD Mark for ResistancePlus® GC

New molecular assay enables rapid antibiotic resistance result to support use of cost effective and ...

Read More >